Dual Incretin Agonist Survodutide Benefits Liver in Phase 3

by admin | Jun 8, 2026 | Health

Spread the love

The glucagon receptor/GLP-1 receptor dual agonist reduces weight, visceral fat, and liver fat.
Medscape Medical News

← Liver-Directed Insulin: A New Way to Reduce Hypoglycemia? Beyond Search and Rescue: What the Japan-South Korea SAREX Revival Really Means →

Written By

Written by Albert Pham, News Curator and Blogger

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Oct 12, 2026 | albertpham, Economy_finances, Health

McDonald’s is expanding its chicken menu and specialty beverages to gain market share by 2030, challenge competitors and attract more customers.

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Oct 12, 2026 | albertpham, Health, Travel

Canadian women are travelling to Mexico for endometriosis treatment after facing long wait times, highlighting gaps in specialist care and women’s health services.

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

Oct 12, 2026 | albertpham, Health

Frequent thirst, fatigue, blurred vision and unexplained weight changes may signal type 2 diabetes. Learn the warning signs and when to seek medical advice.

Dual Incretin Agonist Survodutide Benefits Liver in Phase 3

Written By

Related Posts

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated